Abstract 159 Table 1
| Endpoints | CT<30 min (n=76) | CT 30–60 min (n=150) | CT 60–90 min (n=155) | CT 90–120 min (n=142) | CT>120 min (n=132) | P-value | |
|---|---|---|---|---|---|---|---|
| % Non-Compliance* | 46.0% (35/76) | 38.0% (57/150) | 37.4% (58/155) | 26.1% (37/142) | 26.5% (35/132) | 0.007 | |
| 1 Year Survival | 86.8% | 93.3% | 89.6% | 92.3% | 94.7% | 0.270 | |
| 1 Year Freedom from Any-Treated Rejection | 85.3% | 84.7% | 84.5% | 88.7% | 86.4% | 0.857 | |
| 1 Year Freedom from Acute Cellular Rejection | 94.7% | 91.3% | 94.2% | 95.0% | 93.9% | 0.800 | |
| 1 Year Freedom from Antibody-Mediated Rejection | 94.7% | 95.3% | 97.4% | 96.5% | 96.2% | 0.851 | |
| 1 Year Freedom from Infection | 51.3% | 52.0% | 46.5% | 61.3% | 50.0% | 0.169 | |
*120 min, p=0.006.